Skoči na glavni sadržaj

Pregledni rad

Anti-IgE therapy with omalizumab in asthma and allergic rhinitis

SLAVICA DODIG
DARKO RICHTER
IVANA CEPELAK
BOJAN BENKO


Puni tekst: engleski pdf 118 Kb

str. 123-138

preuzimanja: 1.388

citiraj


Sažetak

The pharmacology, efficacy, dosage, adverse effects, and economics of anti IgE (omalizumab) are discussed. Omalizumab is the generic name for the human/murine chimeric (recombinant humanized) monoclonal IgG antibody. Anti-IgE prevents IgE from attaching to effector cells, and thereby blunts IgE-mediated inflammatory responses. After subcutaneous administration its absorption is slow, reaching peak concentration in serum after an average of 7-8 days. At recommended doses, serum free IgE levels decrease within 1 hour following the first dose and maintained between doses. Dose and dosing frequency are adjusted according to body mass and serum total IgE concentration before the start of treatment. Omalizumab administered subcutaneously is an effective treatment for add-on therapy in patients with poorly controlled, moderate-to-severe allergic asthma and allergic rhinitis (adults and adolescents >12 years). It reduces the requirement for inhaled corticosteroids while protecting against disease exacerbation. Omalizumab is well tolerated, but the safety profile requires long-term assessment in adults as well as in children.

Ključne riječi

asthma; allergic rhinitis; therapy; anti-IgE; omalizumab

Hrčak ID:

16751

URI

https://hrcak.srce.hr/16751

Datum izdavanja:

1.6.2005.

Podaci na drugim jezicima: hrvatski

Posjeta: 3.175 *